Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.65 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.65 |
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 6/20 | 0.52 |
| ▸ | PPARG | P37231 | 5/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14343235 | 1.00 | ITGB3 (0.65) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL16909032 | 1.00 | ITGB3 (0.65) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL8668331 | 0.90 | ITGB3 (0.65) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL8669351 | 0.90 | ITGB3 (0.65) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL16993952 | 0.90 | ITGB3 (0.65) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL5111802 | 0.89 | ITGB3 (0.52) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL5111794 | 0.89 | ITGB3 (0.52) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL13654528 | 0.88 | ITGB3 (0.62) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL3865100 | 0.87 | ITGB3 (0.64) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL3865096 | 0.87 | ITGB3 (0.64) | ITGB3ITGA2BACEPTPN1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552823-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-20250353870-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2025-11-20 | — | — | US | disclosed |
| US-12312378-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2025-05-27 | — | — | US | disclosed |
| CN-118290691-A | Bio-based antibacterial self-repairing medical polyurethane and preparation method thereof | 陕西科技大学 | 2024-07-05 | — | — | CN | disclosed |
| US-20240051982-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-02-15 | — | — | US | disclosed |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20220411461-A1 | METHODS OF MAKING INCRETIN ANALOGS | ELI LILLY AND COMPANY | 2022-12-29 | — | — | US | disclosed |
| WO-2022185319-A1 | UBIQUITIN LIGASE KPC1-PEPTIDE BASED PROTEOLYSIS TARGETING CHIMERAS (PROTAC) AND USES THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2022-09-09 | — | — | WO | disclosed |
| EP-1897550-A2 | Prodrugs of Excitatory Amino Acids | Eli Lilly & Company (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20060167008-A1 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | ELANCO ANIMAL HEALTH IRELAND LIMITED (IE) | 2006-07-27 | — | — | US | disclosed |
| US-20050222231-A1 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | US | disclosed |
| EP-1551804-A1 | SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | Janssen Pharmaceutica N.V. (BE) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004056772-A1 | SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004033428-A1 | SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-04-22 | — | — | WO | disclosed |
| EP-0749429-B1 | 3,5-DISUBSTITUTED AND 3,5,6-TRISUBSTITUTED 2-ISOXAZOLINES AND ISOXAZOLES, PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS | HOECHST AG (DE) | 1999-06-30 | — | — | EP | disclosed |
| US-5814627-A | ANTIINFLAMMATORY AGENTS, ASTHMA; RHEUMATIC AND AUTOIMMUNE DISEASES; INHIBITORS OF LEUKOTRIENES, CYTOKINES, E.G. INTERLEUKINS, OXYGEN RADICALS AND PROTEASES | HOECHST AKTIENEGESELLSCHAFT (DE) | 1998-09-29 | — | — | US | disclosed |
| EP-0749429-A1 | 3,5-DISUBSTITUTED AND 3,5,6-TRISUBSTITUTED 2-ISOXAZOLINES AND ISOXAZOLES, PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-12-27 | — | — | EP | disclosed |
| WO-1995024397-A1 | 3,5-DISUBSTITUTED AND 3,5,6-TRISUBSTITUTED 2-ISOXAZOLINES AND ISOXAZOLES, PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167008-A1 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | NPSR1, VIP, TACR1 | ITGB3 1543/4885ITGA2B 1388/4885ACE 2095/4885 |
| US-20250353870-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | ITGB3 1429/4885ITGA2B 1060/4885ACE 605/4885 |
| US-20240051982-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | OGT, UGGT1, FUT6 | ITGB3 1757/4885ITGA2B 1412/4885ACE 925/4885 |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, GLA | ITGB3 1927/4885ITGA2B 1511/4885ACE 1293/4885 |
| US-12552823-B2 | Glucosamine derivatives and pharmaceutical uses thereof | SOST, FUT6, SLC5A1 | ITGB3 774/4885ITGA2B 1181/4885ACE 1734/4885 |
| US-20050222231-A1 | Prodrugs of excitatory amino acids | SLC1A2, SLC1A1, SLC1A3 | ITGB3 4476/4885ITGA2B 4089/4885ACE 320/4885 |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | ITGB3 1429/4885ITGA2B 1060/4885ACE 605/4885 |
| US-20220411461-A1 | METHODS OF MAKING INCRETIN ANALOGS | IAPP, GLP1R, GIPR | ITGB3 4549/4885ITGA2B 4735/4885ACE 736/4885 |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | OGT, UGGT1, GLA | ITGB3 1429/4885ITGA2B 1060/4885ACE 605/4885 |
| US-12312378-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, FUT6 | ITGB3 1757/4885ITGA2B 1412/4885ACE 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.